India Business News: The Indian drug regulator has granted approval to ImmunoACT for its CAR-T cell therapy NexCAR19, designed to treat certain types of blood cancers. The
The Central Drugs Standard Control Organisation (CDSCO) had set the October 1 deadline for bringing ‘class C and ‘class D medical devices under regulation as part of quality control efforts. To obtain the licences several manufacturers had submitted applications, but the government failed to provide them on time.
Samples of syrups manufactured by two pharmaceutical companies based in Gujarat and Tamil Nadu have been found to have contaminants ethylene glycol and diethylene glycol
NEW DELHI (Reuters) -India's drug regulator has found that a cough syrup and an anti-allergy syrup made by Norris Medicines are toxic, according to a government report, months after Indian-made cough syrups were linked to 141 children's deaths worldwide. The medicines were contaminated either with diethylene glycol (DEG) or ethylene glycol (EG), the same contaminants found in the cough syrups that caused the deaths in Gambia, Uzbekistan and Cameroon since the middle of last year. This is the fir
October 1 was the deadline for bringing ‘class C and ‘class D medical devices – indicating ‘moderate and ‘high risk – under CDSCO regulation as part of a government decision to make it mandatory for all imported and locally manufactured medical devices sold in the country to be certified by the drug regulator before they enter the market to ensure quality.